Tagged with GSK,

GSK In conversation at the FT Global Pharmaceutical and Biotechnology Conference in London,* an energetic Emma Walmsley discussed the strategic and cultural shifts she has implemented in her two and a half years as CEO of iconic British firm GSK, the increasingly important intersection between technology and pharma, and countering the…

Sweden Niclas Källbom Karlsson, general manager of GSK Sweden, reflects on his first five years of heading the local affiliate, in which the company has emerged as a leader in the speciality respiratory medicines, vaccines and HIV area. With a new wave of products to be launched, he highlights the importance…

Egypt Amre Mamdouh, vice president & area general manager for Egypt and North Africa at GSK, explains how GSK has been able to hold its leadership position in Egypt despite economic difficulties. He also highlights the government’s prioritization of healthcare and the role of GSK as a partner of national campaigns,…

AI GSK’s Richard Saynor outlines the ways in which an increased embrace of technologies which utilise artificial intelligence can help improve health literacy and therefore patient outcomes.   In healthcare, AI has the potential to improve drug discovery, development and manufacturing, and enhance interactions with customers, doctors and patients As a…

France Josephine Yang Comiskey, president of GSK France, gives insights into GSK’s corporate culture, portfolio and priorities in France. She also highlights the need for collaboration and a better dialogue between industry and authorities, to ensure quicker market access for innovative products in the country.   We welcome the fact that…

Korea Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for GSK – vaccines, HIV and respiratory treatments, and provides an insight into how GSK can best utilize Korea’s strong environment…

UK The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products with a market share of 7.3 percent.   This move will see GSK effectively split into two separate businesses –…

Cyprus Mario Sciberras, former general manager for Malta and Gibraltar became general manager for Cyprus, Malta, and Gibraltar in 2016. In this interview, he touches on themes of transparency, GSK’s positioning on the market and its vaccination strategy for the coming years. What have been your main priorities since taking over…

GSK KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide…

Brexit Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms ever closer, industry professionals fervently speculate on how it will affect the country’s position as one of the world’s great…

Turkey Selim Giray, the recently appointed VP and general manager of GSK Turkey, provides insights into the company’s eye-catching footprint and commitment to Turkey, his ambition to integrate into the market’s Top Four ranking in the coming years, as well as his aspirations to see the industry and the government work…

Pharma What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets virtual objects against the backdrop of the real world—as in Pokemon Go, the augmented reality smartphone craze of 2016—or simply…